PerkinElmer (NYSE:PKI) announced today that it launched its PKeye workflow monitor for remotely managing and monitoring workflows. Waltham, Massachusetts–based PerkinElmer’s cloud-based PKeye workflow monitor enables laboratory personnel to remotely handle PerkinElmer instruments and workflows in real-time through 24/7 access and visibility into laboratory operations. Get the full story at our sister site, MassDevice.
PerkinElmer announces Street-beating Q2, plans to acquire BioLegend for $5.3B
PerkinElmer (NYSE:PKI) today posted Street-beating second-quarter revenues and announced the $5.3 billion acquisition of BioLegend. The Waltham, Mass.-based company posted profits of $245.9 million, or $2.19 per share, on sales of $1.2 billion for the three months ended July 4, 2021, for a 79.3% bottom-line gain on sales growth of 51.3%. Get the full story at…
PerkinElmer launches its first cell painting kit
PerkinElmer (NYSE:PKI) announced today that it launched the first cell painting kit as part of its PhenoVue cellular imaging reagent portfolio. Waltham, Mass.-based PerkinElmer’s new range of reagents utilizes the company’s expertise in cellular imaging and high-content screening while working with its microplates, automation offerings and software to allow researchers to better understand diseases and develop…
PerkinElmer launches open data site for COVID-19 treatment research
PerkinElmer recently launched an online, open-access COVID-19 data dashboard for the global scientific community. The dashboards are powered by the company’s data analytics and data visualization solutions to help researchers quickly and easily leverage large amounts of drug compounds and clinical trial data. The COVID-19 dashboards are supported by PerkinsElmer’s Signals Lead Discovery and the…
PerkinElmer expects strong Q2 results from COVID-19 testing
PerkinElmer (NYSE:PKI) said today that it anticipates sales growth of approximately 12% for the second quarter, fueled by demand for COVID-19 tests and related products. The Waltham, Mass.-based diagnostic and scientific instrument company said demand for its RT-PCR and serology tests, RNA extraction systems and kits and automated liquid handling instrumentation was particularly robust. COVID-19 related…
Report: PerkinElmer under investigation for Medicare fraud
PerkinElmer (NYSE:PKI) is under federal scrutiny for alleged involvement in a scam to bill Medicare for tens of thousands of unnecessary genetic cancer tests, according to a report by Reuters. The news agency cited three unidentified sources and government documents linking the Waltham, Mass.-based diagnostic and scientific instrument company to the probe. PerkinElmer acknowledged that it…
New PerkinElmer offerings meant to streamline analysis for a variety of labs
PerkinElmer recently announced that it has expanded its analysis and automation portfolio for quality, safety and content testing. The company geared the new offerings for pharmaceutical, semiconductor, biomonitoring, food, materials and academia labs. They’re supposed to help streamline workflows, sharpen insights and meet regulations. Go to our WTWH Media sister site R&D World for the…